The week in pharma: action, reaction and insight – week to June 3, 2022
By Barbara Obstoj-Cardwell. Editor
M&A featured in last week’s news, with UK pharma major GlaxoSmithKline (GSK) announcing on Tuesday that is buying privately-held vaccine maker Affinivax for up to $3.3 billion, and on Friday the USA’s Bristol Myers Squibb revealed a $4.1 billion offer to acquire Turning Point Therapeutics and its lung cancer candidate repotrectinib. On the research front, US biotech Eledon Pharmaceuticals presented positive Phase IIa results for its investigational amyotrophic lateral sclerosis (ALS) tegoprubart, and Sage Therapeutics, with partner Biogen, released Phase III data on their zuranolone in the treatment of postpartum depression drug. Also, France’s Sanofi and US partner Regeneron have restructured their licensing deal for the immune-oncology drug Libtayo, with Regeneron gaining worldwide exclusive rights.
GSK goes back to its vaccine bread and butter
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze